Content
10/25/2023
Chicago, IL USA
Flashpoint Therapeutics
completed $10 million Seed Round funding. Investors include
Beta Lab (lead), CS Ventures.
About
Flashpoint Therapeutics is developing a new class of cancer immunotherapies through rational nanoscale design of therapeutic architecture to optimize anti-tumor immune response.
Across 9 in vivo mouse studies, Flashpoint nanostructures have achieved near curative or curative efficacy using the same therapeutic components that are ineffective in conventional formulations.
Flashpoint leverages 20 years of research from the lab of co-founder Dr. Chad Mirkin -- Professor at Northwestern and Director of the International Institute for Nanomedicine, who has founded 3 public or acquired companies and commercialized over 2,000 products.
Flashpoint will efficiency move development candidates through clinical testing by leveraging established GMP compliant manufacturing capabilities and FDA approved regulatory paths previously developed to support clinical studies based on components of Flashpoint platform.
Flashpoint has assembled an experienced leadership team over core functional areas and is poised to initiate building the company's asset pipeline through partnerships and in-house development.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
